Compare Summit Therapeutics Inc (SMMT) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Atlassian Corporation PLC — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Atlassian Corporation PLC trades at $206.79 (market cap $51.53B). The key difference: Atlassian Corporation PLC is far larger — about 3.8× Summit Therapeutics Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Atlassian Corporation PLC for 65 Days on average.
| SMMT | TEAM | |
|---|---|---|
Market Cap | $13.71B | $51.53B |
Volume | 6,173,057 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $26.38 | $203.57 |
52-Week Low | $12.43 | $57.15 |
Typical Hold Time | 16 Days | 65 Days |
Enterprise Value | $13.04B | $51.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Atlassian (TEAM) trades at $203.57, up 4.04% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth from $5.22B in 2025 to projected $6.6B in 2026, though it remains unprofitable with a -0.82% net margin. Recent earnings beats and strong analyst sentiment (69.77% buy ratings) support the positive outlook, while the stock trades above the consensus price target of $191.16.
TEAM offers growth exposure to enterprise software and AI adoption, with cloud revenue up 31% and 95% subscription mix. However, high valuations (P/S 8.06, EV/EBITDA 242.85) and persistent losses create risk if growth slows. The stock faces resistance near $206-212 with RSI suggesting potential overbought conditions near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
